Last reviewed · How we verify
Neupogen 5µg/kg/day
Neupogen (filgrastim) stimulates the bone marrow to produce and release neutrophils, increasing white blood cell counts to prevent or treat infections in immunocompromised patients.
Neupogen (filgrastim) stimulates the bone marrow to produce and release neutrophils, increasing white blood cell counts to prevent or treat infections in immunocompromised patients. Used for Chemotherapy-induced neutropenia (CIN) in cancer patients, Severe chronic neutropenia, Peripheral blood progenitor cell (PBPC) mobilization for autologous transplantation.
At a glance
| Generic name | Neupogen 5µg/kg/day |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | Granulocyte colony-stimulating factor (G-CSF) |
| Target | G-CSF receptor (GCSFR) |
| Modality | Biologic |
| Therapeutic area | Oncology, Hematology, Immunology |
| Phase | Phase 3 |
Mechanism of action
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow. This binding promotes proliferation, differentiation, and activation of neutrophil precursors, leading to increased production and mobilization of mature neutrophils into the bloodstream. It is used to mitigate chemotherapy-induced neutropenia and mobilize peripheral blood progenitor cells for transplantation.
Approved indications
- Chemotherapy-induced neutropenia (CIN) in cancer patients
- Severe chronic neutropenia
- Peripheral blood progenitor cell (PBPC) mobilization for autologous transplantation
Common side effects
- Bone pain
- Headache
- Fatigue
- Injection site reactions
- Splenomegaly
- Elevated uric acid
Key clinical trials
- Epigenetic Reprogramming in Relapse/Refractory AML (PHASE1)
- Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML (PHASE3)
- A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients (PHASE3)
- Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation (NA)
- Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neupogen 5µg/kg/day CI brief — competitive landscape report
- Neupogen 5µg/kg/day updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI